ReviewOncology letters2026
Role of tumor necrosis factor receptor superfamily member 19 in cancer: Diverse functions and therapeutic potential (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor receptor superfamily member 19 (TNFRSF19), as a principal member of the TNFRSF, is highly expressed across a variety of invasive neoplastic diseases. It facilitates the evasion of host anti-cancer immune responses by remodelling the immunosuppressive cancer microenvironment, thereby playing a key role in immune evasion; conversely, inhibiting its expression can significantly delay cancer progression. This article provides a systematic review of the functional diversity of this molecule, its encoding of two functionally distinct isoforms via differential transcription initiation, the mechanisms underlying its pro-cancer and anti-cancer effects in various cancer diseases, and its potential value in targeted intervention strategies, clinical translation and the regulation of the cancer immune microenvironment, thereby providing a theoretical foundation for further mechanistic investigations in oncology and for the development of combinatorial immunotherapeutic regimens incorporating TNFRSF19-targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.